Publicacions - IR Sant Pau

Cercar

01/01/2023 External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort

Van Straalen K.R., Tzellos T., Alavi A., Benhadou F., Cuenca-Barrales C., Daxhelet M., Daoud M., Efthymiou O., Giamarellos-Bourboulis E.J., Guillem P., Gulliver W., Jemec G.B.E., Katoulis A., Koenig A., Lazaridou E., Lowes M.A., Marzano A.V., Matusiak L., Molina-Leyva A., Moltrasio C., Pinter A., Potenza C., Prens E.P., Romaní J., Saunte D.M., Sayed C., Skroza N., Stergianou D., Szepietowski J.C., Trigoni A., Vilarrasa E., Kyrgidis A., Zouboulis C.C., Van Der Zee H.H.. External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort. DERMATOLOGY. 2023; 239(3)DOI:10.1159/000528968. PMID:36630943. IF:3.000(Q2/4D).

01/01/2023 Chronic prurigo: Insufficient disease control in spite of high healthcare usage

Pereira M.P., Weisshaar E., Halvorsen J.A., Wallengren J., Legat F.J., Garcovich S., Savk E., Reich A., Bozek A., Lvov A., Bobko S., Metz M., Streit M., Misery L., Brenaut E., Serra-Baldrich E., Gonçalo M., Szepietowski J.C., Augustin M., Nau T., Zeidler C., Ständer S.. Chronic prurigo: Insufficient disease control in spite of high healthcare usage. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(6)DOI:10.1111/jdv.18903. PMID:36682045. IF:8.500(Q1/1D).

01/01/2023 Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials

Blauvelt A., Thyssen J.P., Guttman-Yassky E., Bieber T., Serra-Baldrich E., Simpson E., Rosmarin D., Elmaraghy H., Meskimen E., Natalie C.R., Liu Z., Xu C., Pierce E., Morgan-Cox M., Garcia Gil E., Silverberg J.I.. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(6)DOI:10.1093/bjd/ljad022. PMID:36994947. IF:11.000(Q1/1D).

01/01/2023 [Translated article] Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis: Consensus-Based Recommendations From a Multidisciplinary Group of Experts [Abordaje común del paciente con psoriasis y riesgo de esteatosis hepática metabólica: recomendaciones de un grupo de expertos multidisciplinar]

Carrascosa J.M., Vilarrasa E., Belinchón I., Herranz P., Crespo J., Guimerá F., Olveira A.. [Translated article] Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis: Consensus-Based Recommendations From a Multidisciplinary Group of Experts [Abordaje común del paciente con psoriasis y riesgo de esteatosis hepática metabólica: recomendaciones de un grupo de expertos multidisciplinar]. Actas Dermo-Sifiliograficas. 2023; 114(5)DOI:10.1016/j.ad.2023.04.013. PMID:37068635. IF:(Q/D).

01/01/2023 Reply to: “Comment on ‘Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: An observational study to assess prevalence and causes’”

Schneller-Pavelescu L., Vergara-de Caso E., Martorell A., Romaní J., Lázaro M., Vilarrasa E., Díaz-Ley B., Vázquez-Osorio I., Segura Palacios J.M., Azaña J.M., González-López M.A., Cañueto J., Molina-Leyva A., Leiva-Salinas M., Navarro-Triviño F.J., Sánchez-Payá J., Pascual J.C.. Reply to: “Comment on ‘Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: An observational study to assess prevalence and causes’”. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 88(5)DOI:10.1016/j.jaad.2019.03.006. PMID:30872153. IF:12.800(Q1/1D).

01/01/2023 Skin cancer special issue in Skin Health and Disease

Yélamos O., Geller S., Tokez S.. Skin cancer special issue in Skin Health and Disease. Skin Health And Disease. 2023; 3(2)DOI:10.1002/ski2.224. PMID:37013119. IF:(Q/D).

01/01/2023 [Translated article] BAP1-inactivated Melanocytic Tumor: Dermoscopic Features to Aid Diagnosis [Tumor melanocítico inactivado a BAP1: claves para su diagnóstico dermatoscópico]

Fustà-Novell X., García-Herrera A., Yélamos O.. [Translated article] BAP1-inactivated Melanocytic Tumor: Dermoscopic Features to Aid Diagnosis [Tumor melanocítico inactivado a BAP1: claves para su diagnóstico dermatoscópico]. Actas Dermo-Sifiliograficas. 2023; 114(2)DOI:10.1016/j.ad.2022.11.008. PMID:36464005. IF:(Q/D).

01/01/2023 The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease

Olveira A., Augustin S., Benlloch S., Ampuero J., Suárez-Pérez J.A., Armesto S., Vilarrasa E., Belinchón-Romero I., Herranz P., Crespo J., Guimerá F., Gómez-Labrador L., Martín V., Carrascosa J.M.. The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease. Life-Basel. 2023; 13(2)DOI:10.3390/life13020419. PMID:36836776. IF:3.200(Q1/3D).

01/01/2023 Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials

Simpson E.L., Pink A.E., Blauvelt A., Gooderham M., Armstrong A.W., Worm M., Katoh N., Peris K., Puig L., Barbarot S., Mark T., Steffensen L.A., Tindberg A.-M., Wollenberg A.. Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2023; 24(6)DOI:10.1007/s40257-023-00806-3. PMID:37682422. IF:8.600(Q1/1D).

01/01/2023 Race, Ethnicity, and Ancestry: A Short Review and Proposal for Consistent Classifications in Dermatology

Puig L.. Race, Ethnicity, and Ancestry: A Short Review and Proposal for Consistent Classifications in Dermatology. Actas Dermo-Sifiliograficas. 2023; 114(10)DOI:10.1016/j.ad.2023.07.013. PMID:37482290. IF:(Q/D).

01/01/2023 The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study

Rivera-Díaz R., Pozo T., Alfageme F., Díaz Ley B., Osorio G.F., Chico R., Vilarrasa E., Silvente C., Ciudad Blanco C., Romaní J., Martorell A., Fernández P., Romero Ferreiro C., Molina Leyva A.. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study. Actas Dermo-Sifiliograficas. 2023; 114(9)DOI:10.1016/j.ad.2023.06.013. PMID:37331620. IF:(Q/D).

01/01/2023 Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results

Pereyra-Rodriguez J.J., Herranz P., Figueras-Nart I., Perez B., Elosua M., Munera-Campos M., Melgosa-Ramos J., Zaragoza V., Silvestre J.F., Campos-Domínguez M., Guilabert A., Miquel J., Alcantara-Luna S., de la Cueva P., Serra-Baldrich E., Armario-Hita J.C.. Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY. 2023; 33(3)DOI:10.18176/jiaci.0831. PMID:35671128. IF:6.700(Q1/2D).

01/01/2023 Cardiovascular Screening Practices and Statin Prescription Habits in Patients with Psoriasis among Dermatologists, Rheumatologists and Primary Care Physicians

Berna-Rico E., ABBAD-JAIME DE ARAGON C., Garcia-Aparicio Á., Palacios-Martinez D., Ballester-Martínez A., Carrascosa J.-M., DE LA CUEVA P., Anton C., Azcarraga-Llobet C., Garcia-Mouronte E., DE NICOLAS-RUANES B., Puig L., Jaen P., Mehta N.N., Gelfand J.M., Gonzalez-Cantero Á.. Cardiovascular Screening Practices and Statin Prescription Habits in Patients with Psoriasis among Dermatologists, Rheumatologists and Primary Care Physicians. ACTA DERMATO-VENEREOLOGICA. 2023; 103DOI:10.2340/actadv.v103.5087. PMID:36987537. IF:3.500(Q1/3D).

01/01/2023 Reflectance Confocal Microscopy Terminology in Spanish: A Delphi Consensus Study.

Abarzua-Araya A, Bañuls J, Cabo H, Carrera C, Gamo R, González S, Jaimes N, Navarrete-Dechent C, Pérez Anker J, Roldán-Marín R, Segura S, Yélamos O, Puig S, Malvehy J. Reflectance Confocal Microscopy Terminology in Spanish: A Delphi Consensus Study.. Actas Dermo-Sifiliograficas. 2023; 115(3)DOI:10.1016/j.ad.2023.10.014. PMID:37890615. IF:(Q/D).

01/01/2023 Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain.

Artime E, Serra E, Mert C, Díaz-Cerezo S, Huete T, Hernández-Subirá I, Lledo-Bryant L, Sicras-Mainar A. Real-World Treatment Patterns, Resource Use and Costs in Adult Patients With Atopic Dermatitis Receiving Systemic Treatment: Derma-Atopic Study in Spain.. Actas Dermo-Sifiliograficas. 2023; 114(1)DOI:10.1016/j.ad.2022.08.015. PMID:36030827. IF:(Q/D).

01/01/2023 Tratamiento comparativo de lesiones mucocutáneas en pacientes con telangiectasia hemorrágica hereditaria con láser dual secuencial de colorante pulsado y neodimio: itrio-aluminio-granate versus neodimio: itrio-aluminio-granate solo: un estudio controlado aleatorizado doble ciego con evaluación de la calidad de vida

Cubiró X., Garcia-Melendo C., Morales-Munera C.E., Riera-Mestre A., Torres-Iglesias R., Villanueva B., Puig L., Baselga E.. Tratamiento comparativo de lesiones mucocutáneas en pacientes con telangiectasia hemorrágica hereditaria con láser dual secuencial de colorante pulsado y neodimio: itrio-aluminio-granate versus neodimio: itrio-aluminio-granate solo: un estudio controlado aleatorizado doble ciego con evaluación de la calidad de vida. Actas Dermo-Sifiliograficas. 2023; 115(3)DOI:10.1016/j.ad.2023.10.017. PMID:37913989. IF:(Q/D).

01/01/2023 Corrigendum: The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases(Front. Immunol., (2023), 14, (1191782), 10.3389/fimmu.2023.1191782)

Navarro-Compán V., Puig L., Vidal S., Ramírez J., Llamas-Velasco M., Fernández-Carballido C., Almodóvar R., Pinto J.A., Galíndez-Aguirregoikoa E., Zarco P., Joven B., Gratacós J., Juanola X., Blanco R., Arias-Santiago S., Sanz J.S., Queiro R., Cañete J.D.. Corrigendum: The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases(Front. Immunol., (2023), 14, (1191782), 10.3389/fimmu.2023.1191782). Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1332177. PMID:. IF:(Q/D).

30/12/2022 The Benefits of Early versus Late Therapeutic Intervention in Fabry Disease.

Furlano M, Ars E, Matamala A, Brossa V, Martí J, Del Prado-Venegas M, Crespi J, Roe E, Torra R. The Benefits of Early versus Late Therapeutic Intervention in Fabry Disease.. Case Reports In Genetics. 2022; 2022DOI:10.1155/2022/3208810. PMID:36619006. IF:(Q/D).

01/06/2025 Baseline Characteristics and Treatment Patterns of Patients with Atopic Dermatitis Treated with Oral Systemic Therapies: An Interim Analysis of the AD-REAL Study

Augustin, M, Serra-Baldrich, E, Seneschal, J, Grond, S, Lampropoulou, A, Elrayes, M, Ogwu, S, de la Torre, I, Bewley, A, Pinter, A. Baseline Characteristics and Treatment Patterns of Patients with Atopic Dermatitis Treated with Oral Systemic Therapies: An Interim Analysis of the AD-REAL Study. ADVANCES IN THERAPY. 2025; 42(6)DOI:10.1007/s12325-025-03137-3. PMID:40192965. IF:4.000(Q1/3D).

01/06/2025 Cholinergic Pruritus as an Early Sign of Essential Thrombocythemia With Therapeutic Response to Ruxolitinib

Mateu-Arrom, L, Serra-Baldrich, E, Puig, L. Cholinergic Pruritus as an Early Sign of Essential Thrombocythemia With Therapeutic Response to Ruxolitinib. Actas Dermo-Sifiliograficas. 2025; 116(6)DOI:10.1016/j.ad.2023.09.035. PMID:39947585. IF:(Q/D).

01/05/2025 Oral mucosal papules in an immunosuppressed girl

Peirano, F, Rusiñol, L, Iznardo, H, Carmona-Rocha, E, Puig, L, Roé, E. Oral mucosal papules in an immunosuppressed girl. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2025; 50(5)DOI:10.1093/ced/llaf007. PMID:39775820. IF:2.800(Q2/4D).

01/05/2025 Multicenter, Prospective, Case-Control Study of Exposome in Melanoma

Navarro-Bielsa, A, Gracia-Cazaña, T, Almagro, M, De-la-Fuente-Meira, S, Florez, A, Yélamos, O, Montero-Vilchez, T, González-Cruz, C, Diago, A, Abadías-Granado, I, Fuentelsaz, V, Colmenero, M, Bañuls, J, Arias-Santiago, S, Buendía-Eisman, A, Almenara-Blasco, M, Gil-Pallares, P, Gilaberte, Y. Multicenter, Prospective, Case-Control Study of Exposome in Melanoma. Actas Dermo-Sifiliograficas. 2025; 116(5)DOI:10.1016/j.ad.2024.09.022. PMID:39756676. IF:(Q/D).

01/04/2025 Histological deep margins in cutaneous squamous cell carcinoma of the scalp and risk of recurrence

Verdaguer-Faja, J, Guerra-Amor, A, Ferrándiz-Pulido, C, Abril-Pérez, C, Estrada, RB, Masferrer, E, Lopez-Castillo, D, Deza, G, Leal, L, Marti-Marti, I, Ruiz-Salas, V, Yébenes, M, Martin, LM, Baliu, C, Castany, A, Boada, A, Toll, A, Jaka, A. Histological deep margins in cutaneous squamous cell carcinoma of the scalp and risk of recurrence. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2025; 39(4)DOI:10.1111/jdv.20250. PMID:39036869. IF:8.000(Q1/1D).

01/04/2025 Parental Assessment of Infantile Hemangioma Cosmetic Clinical Outcomes: Results of the Spanish Hemangioma Nationwide Prospective Cohort

Colmenero-Sendra, M, del Boz-González, J, Torres, EB, Bernabéu-Wittel, J, Roé-Crespo, E, Vicente, A, Valdivieso-Ramos, M, Martín-Santiago, A, Palencia-Pérez, SI, Montserrat-García, MT, Azón-Masoliver, A, Dañino, M, Prims, CT, Prat, C, Giacaman, A, Domínguez-Cruz, JJ, Alonso, AB, Grau-Pérez, M, Descalzo, MA, García-Doval, I. Parental Assessment of Infantile Hemangioma Cosmetic Clinical Outcomes: Results of the Spanish Hemangioma Nationwide Prospective Cohort. Actas Dermo-Sifiliograficas. 2025; 116(4)DOI:10.1016/j.ad.2024.06.010. PMID:39032773. IF:(Q/D).

01/03/2025 The impact on pain and mental health in patients with hidradenitis suppurativa: Results from the HS Uncovered global patient survey

Kokolakis, G, Guillem, P, Vilarrasa, E, Alarcon, I, Go, M, Newbold, G, Mamareli, A, Richardson, C, McGrath, B, Kirby, JS. The impact on pain and mental health in patients with hidradenitis suppurativa: Results from the HS Uncovered global patient survey. EXPERIMENTAL DERMATOLOGY. 2025; 34DOI:. PMID:. IF:3.100(Q2/3D).

01/03/2025 Lymphedema in hidradenitis suppurativa: A multicenter case series

Garbayo-Salmons, P, Vilarrasa, E, Haselgruber, S, Gamissans, M, Ciudad, C, Martorell, A, Aguayo-Ortiz, RS, Romani, J, Fornons-Servent, R, Molina-Leyva, A. Lymphedema in hidradenitis suppurativa: A multicenter case series. EXPERIMENTAL DERMATOLOGY. 2025; 34DOI:. PMID:. IF:3.100(Q2/3D).

01/03/2025 Major predictors of remission in hidradenitis suppurativa: An 8-year survival study with adalimumab

Vilarrasa, E, Salmons, PG, Bassas-Vila, J, Mora, V, Fuertes, I, Luque, M, Fornons-Servent, R, Martin, G, Aguayo-Ortiz, RS, Ceravalls, J, Mollet, J, Gómez, A, Masferrer, E, Corral, O, Matas, C, Romaní, J. Major predictors of remission in hidradenitis suppurativa: An 8-year survival study with adalimumab. EXPERIMENTAL DERMATOLOGY. 2025; 34DOI:. PMID:. IF:3.100(Q2/3D).

01/03/2025 Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy

Silverberg, JI, Bieber, T, Paller, AS, Beck, L, Kamata, M, Puig, L, Wiseman, M, Ezzedine, K, Irvine, AD, Foley, P, Del Rosso, J, Gold, LS, Johansson, E, Dossenbach, M, Gallo, G, Akmaz, B, Casillas, M, Karlsson, A, Curteis, T, Chovatiya, R. Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy. Dermatology and Therapy. 2025; 15(3)DOI:10.1007/s13555-025-01357-7. PMID:39953372. IF:4.200(Q1/1D).

01/03/2025 Bimekizumab demonstrates effective responses and safety in hidradenitis suppurativa: Short-term real-world observational multicentric study from Spain

Mansilla-Polo, M, Benvant, MP, Fernández-Crehuet, P, Vilarrasa, E, Albanell-Fernández, C, Morales-Tedone, E, Rausell-Félix, F, Alcalá-García, R, Matellanes-Palacios, M, Martín-Ezquerra, G, Alfageme, F, Blanco, CC, López-Villaescusa, MT, Salmons, PG, Martorell, A, Muñoz, BE, Navarro-Blanco, F, Torregrosa, DM, Barrales, CC, Leyva, AM, Botella-Estrada, R. Bimekizumab demonstrates effective responses and safety in hidradenitis suppurativa: Short-term real-world observational multicentric study from Spain. EXPERIMENTAL DERMATOLOGY. 2025; 34DOI:. PMID:. IF:3.100(Q2/3D).

01/03/2025 Advanced Doppler Ultrasound Insights: A Multicenter Prospective Study on Healthy Skin

Giavedoni, P, Romaní, J, de Cabo, F, García-Martínez, FJ, Quintana-Codina, M, Roè-Crespo, E, de Vega, IF, Soria-Gili, X, Aguayo-Ortiz, R, Garbayo-Salmons, P, Castillo, G, Vidal-Sarró, D, Mollet, J, Serra, L, Gonzalez, C, López-Trujillo, E, Just, M, Combalia, M, Podlipnik, S, Malvehy, J, Wortsman, X. Advanced Doppler Ultrasound Insights: A Multicenter Prospective Study on Healthy Skin. Diagnostics. 2025; 15(5)DOI:10.3390/diagnostics15050569. PMID:40075816. IF:3.300(Q1/2D).

10/02/2025 Global Delphi consensus on treatment goals for generalized pustular psoriasis

Barker, JN, Casanova, E, Choon, SE, Foley, P, Fujita, H, Gonzalez, C, Gooderham, M, Marrakchi, S, Puig, L, Romiti, R, Thaçi, D, Zheng, M, Strober, B. Global Delphi consensus on treatment goals for generalized pustular psoriasis. BRITISH JOURNAL OF DERMATOLOGY. 2025; 192(4)DOI:10.1093/bjd/ljae491. PMID:39844356. IF:9.600(Q1/1D).

03/02/2025 Postswitching discontinuation of biosimilars in psoriasis: registry analyses fall short in addressing real-world biases

Puig, L. Postswitching discontinuation of biosimilars in psoriasis: registry analyses fall short in addressing real-world biases. BRITISH JOURNAL OF DERMATOLOGY. 2025; 192(4)DOI:10.1093/bjd/ljaf003. PMID:39761694. IF:9.600(Q1/1D).

01/02/2025 Patch test results to the Spanish baseline patch test series according to age groups: A multicentric prospective study from 2019 to 2023

Pesqué, D, Planella-Fontanillas, N, Borrego, L, Sanz-Sánchez, T, Zaragoza-Ninet, V, Serra-Baldrich, E, Miquel-Miquel, FJ, Silvestre-Salvador, JF, Córdoba-Guijarro, S, Sánchez-Gilo, A, Mercader-García, P, Navarro-Triviño, FJ, Ortiz-de-Frutos, FJ, Tous-Romero, F, Rodríguez-Serna, M, Melé-Ninot, G, Barrabés-Torrella, C, Ruiz-González, I, Pastor-Nieto, MA, Carrascosa-Carrillo, JM, Gómez-de-la-Fuente, E, Sánchez-Pedreño-Guillén, P, Sánchez-Pérez, J, Pereyra-Rodríguez, JJ, Gatica-Ortega, ME, González-Pérez, R, Pujol, RM, Descalzo, MAG, García-Doval, I, Giménez-Arnau, AM. Patch test results to the Spanish baseline patch test series according to age groups: A multicentric prospective study from 2019 to 2023. CONTACT DERMATITIS. 2025; 92(2)DOI:10.1111/cod.14702. PMID:39394969. IF:4.600(Q1/1D).

01/02/2025 Refractory Lichen Sclerosus Treated With Fractional CO2 Laser-assisted Drug Delivery Photodynamic Therapy Using 5-Aminolevulinic Acid: A Case Series

Mateu-Arrom, L, Yélamos, O, Morales-Munera, CE. Refractory Lichen Sclerosus Treated With Fractional CO2 Laser-assisted Drug Delivery Photodynamic Therapy Using 5-Aminolevulinic Acid: A Case Series. Actas Dermo-Sifiliograficas. 2025; 116(2)DOI:10.1016/j.ad.2024.09.017. PMID:39419378. IF:(Q/D).

01/02/2025 AEDV Expert Document on the Management of Ulcerative Venereal Infections

Morales-Múnera, CE, Montoya, F, de Loredo, N, Sendagorta, E. AEDV Expert Document on the Management of Ulcerative Venereal Infections. Actas Dermo-Sifiliograficas. 2025; 116(2)DOI:10.1016/j.ad.2024.11.012. PMID:39566736. IF:(Q/D).

01/02/2025 Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study

Martorell-Calatayud, A, Santos-Alarcón, S, Sahuquillo-Torralba, A, Rivera-Díaz, R, Belinchón-Romero, I, Ruiz-Genao, D, Romero-Maté, A, Ruiz-Villaverde, R, Ferran-Farrés, M, Gallardo-Hernández, F, Almenara-Blasco, M, Suarez-Perez, JA, González-Cantero, A, Martínez-Lorenzo, E, Fernández-Armenteros, JM, del Alcázar-Viladomiu, E, García-Latasa, J, Rocamora-Durant, V, Ara-Martín, M, Mateu-Puchades, A, Llamas-Velasco, M, Vilarrasa, E, Velasco-Pastor, M, De la Cueva, P, Carrascosa, JM, Magdaleno-Tapial, J. Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study. Actas Dermo-Sifiliograficas. 2025; 116(2)DOI:10.1016/j.ad.2024.02.030. PMID:38452889. IF:(Q/D).

01/01/2025 Cyclosporine for the treatment of chronic spontaneous urticaria refractory to antihistamines and omalizumab: a case series

Mateu-Arrom, L, Giménez-Arnau, AM, Expósito-Serrano, V, Bonfill-Orti, M, Serra-Baldrich, E, Yélamos, O, Spertino, J. Cyclosporine for the treatment of chronic spontaneous urticaria refractory to antihistamines and omalizumab: a case series. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2025; 64(1)DOI:10.1111/ijd.17358. PMID:38940007. IF:3.200(Q1/3D).

01/01/2025 Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

Cerezuela-Fuentes, P, Gonzalez-Cao, M, Puertolas, T, Manzano, JL, Maldonado, C, Yelamos, O, Berciano-Guerrero, MA, Martin-Liberal, J, Muñoz-Couselo, E, Espinosa, E, Drozdowskyj, A, Berrocal, A, Soria, A, Marquez-Rodas, I, Martin-Algarra, S, Quindos, M, Puig, S. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis. Clinical & Translational Oncology. 2025; 27(1)DOI:10.1007/s12094-024-03583-5. PMID:38951438. IF:2.500(Q3/6D).

01/01/2025 Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN-FRT expert consensus

Torres, T, Brembilla, NC, Langley, RG, Warren, RB, Thaci, D, Kolios, AGA, Prinz, JC, Londono-Garcia, A, Nast, A, Santin, M, Goletti, D, Abreu, M, Spuls, P, Boehncke, WH, Puig, L. Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN-FRT expert consensus. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2025; 39(1)DOI:10.1111/jdv.20287. PMID:39149807. IF:8.000(Q1/1D).

01/01/2025 Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology

Carmona-Rocha, E, Rusiñol, L, Puig, L. Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology. Pharmaceutics. 2025; 17(1)DOI:10.3390/pharmaceutics17010091. PMID:39861739. IF:5.500(Q1/1D).

01/01/2025 Erosive Lesions in the Legs of an Elderly Woman

Carmona-Rocha, E, Rusiñol, L, Puig, L. Erosive Lesions in the Legs of an Elderly Woman. INDIAN JOURNAL OF DERMATOLOGY. 2025; 70(1)DOI:10.4103/ijd.ijd_851_23. PMID:39896302. IF:1.300(Q3/7D).

01/01/2025 Secukinumab for Treatment of Plaque Psoriasis in Real-World Clinical Practice in Spain: A Literature Review

Dauden, E, Ortiz-Salvador, JM, Notario, J, Puig, L, Santos-Juanes, J, Herrera-Acosta, E, Gomez-Labrador, L, Ruiz-Villaverde, R. Secukinumab for Treatment of Plaque Psoriasis in Real-World Clinical Practice in Spain: A Literature Review. Journal of Clinical Medicine. 2025; 14(2)DOI:10.3390/jcm14020478. PMID:39860484. IF:2.900(Q1/2D).

01/01/2025 Measurement Assessment of Minimal Disease Activity In Psoriasis in Spain: A National Cross-Sectional Study

Hernández, G, Martin, M, Alonso, S, Romero, I, Salvado, N, Farrés, M, Osuna, C, Bustínduy, M, de Araníbar, JG, Manresa, M, Velasco, M, Ferrer, A, Riesco, M, Genao, D, Ruíz-Villaverde, R, Boquete, L, Martínez, C, Rull, E, Descalzo, MA. Measurement Assessment of Minimal Disease Activity In Psoriasis in Spain: A National Cross-Sectional Study. Actas Dermo-Sifiliograficas. 2025; 116(1)DOI:10.1016/j.ad.2024.05.022. PMID:38876209. IF:(Q/D).

01/01/2025 Measurement Assessment of Minimal Disease Activity in Psoriasis in Spain: A National Cross-Sectional Study

Hernández, GC, Martín, MA, Alonso, SA, Romero, IB, Salvado, NE, Farrés, MF, Osuna, CG, Bustínduy, MG, de Aranibar, JGL, Manresa, MJ, Velasco, ML, Ferrer, AL, Riesco, MR, Genao, DR, Ruíz-Villaverde, R, Boquete, LS, Martínez, CS, Rull, EV, Descalzo, MA. Measurement Assessment of Minimal Disease Activity in Psoriasis in Spain: A National Cross-Sectional Study. Actas Dermo-Sifiliograficas. 2025; 116(1)DOI:10.1016/j.ad.2024.10.009. PMID:. IF:(Q/D).

01/01/2025 Infection Risk and Vaccination in the Management of Psoriasis: Considerations for Biologic Therapy

Mateu-Arrom, L, Puig, L. Infection Risk and Vaccination in the Management of Psoriasis: Considerations for Biologic Therapy. Psoriasis-Targets And Therapy. 2025; 15DOI:10.2147/PTT.S510141. PMID:40237012. IF:(Q/D).

31/12/2024 Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)

Girolomoni, G, Feldman, SR, Egeberg, A, Puig, L, Jung, J, Jung, H, Lee, Y. Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). JOURNAL OF DERMATOLOGICAL TREATMENT. 2024; 35(1)DOI:10.1080/09546634.2024.2434091. PMID:39626886. IF:3.900(Q1/2D).

05/12/2024 Safety in patients with latent tuberculosis who received concomitant anti-tuberculosis medications: analysis of 11 studies of guselkumab in psoriatic disease

Puig, L, Tsai, TF, Soriano, ER, Bhutani, T, Miller, M, Kollmeier, AP, Li, S, You, Y, Li, HW, Patel, H, Lavie, F, Gooderham, M, Londono, A, Lebwohl, M, Nash, P. Safety in patients with latent tuberculosis who received concomitant anti-tuberculosis medications: analysis of 11 studies of guselkumab in psoriatic disease. BRITISH JOURNAL OF DERMATOLOGY. 2024; 191DOI:10.1093/bjd/ljae360.098. PMID:. IF:9.600(Q1/1D).

05/12/2024 Effectiveness of biologics in clinical practice: Month 12 absolute psoriasis area and severity index outcomes from an international observational Psoriasis Study of Health Outcomes

Maul, JT, Bonnekoh, B, Puig, L, McKenzie, R, Lampropoulou, A, Martimianaki, G, Fotiou, K, Pinter, A, Akiror, C. Effectiveness of biologics in clinical practice: Month 12 absolute psoriasis area and severity index outcomes from an international observational Psoriasis Study of Health Outcomes. BRITISH JOURNAL OF DERMATOLOGY. 2024; 191DOI:10.1093/bjd/ljae360.093. PMID:. IF:9.600(Q1/1D).

01/11/2024 An emerging epidemic of allergic contact dermatitis due to phytonadione epoxide (oxidised vitamin K1)

Gatica-Ortega, ME, Pastor-Nieto, MA, Giménez-Arnau, AM, Mercader-García, P, Serra-Baldrich, E, Zaragoza-Ninet, V, Sanz-Sánchez, T, Sánchez-Gilo, A, Pesqué, D, Tous-Romero, F, Ortiz-de-Frutos, FJ, de la Rosa-Fernández, E, Dorta-Alom, S, Elosua-González, M, Gonzalez-Perez, R, Carrascosa-Carrillo, JM, Munera-Campos, M, Silvestre-Salvador, JF, Miquel-Miquel, J, Minguez, AD, Borrego, L. An emerging epidemic of allergic contact dermatitis due to phytonadione epoxide (oxidised vitamin K1). CONTACT DERMATITIS. 2024; 91(5)DOI:10.1111/cod.14675. PMID:39164011. IF:4.600(Q1/1D).

01/11/2024 [Translated article] Consensus on the Diagnostic Algorithm for Chronic Nodular Prurigo

Frutos, JOD, Baldrich, ES, Boixareu, MJT, Hita, JCA, Carrillo, JMC, Nart, IF, Flórez, A, Pinto, PH, Silvestre, JF. [Translated article] Consensus on the Diagnostic Algorithm for Chronic Nodular Prurigo. Actas Dermo-Sifiliograficas. 2024; 115(10)DOI:10.1016/j.ad.2024.09.011. PMID:39260612. IF:(Q/D).

01/11/2024 Four-year maintenance of complete skin clearance with bimekizumab in 10 Spanish patients from the BE RADIANT trial

Ferrer, AL, Romero, IB, Díaz, RR, Pinto, PH. Four-year maintenance of complete skin clearance with bimekizumab in 10 Spanish patients from the BE RADIANT trial. Actas Dermo-Sifiliograficas. 2024; 115(10)DOI:10.1016/j.ad.2023.05.044. PMID:39033804. IF:(Q/D).

01/11/2024 Consensus on the Diagnostic Algorithm for Chronic Nodular Prurigo

de Frutos, JO, Baldrich, ES, Boixareu, MJT, Hita, JCA, Carrillo, JMC, Nart, IF, Menéndez, AF, Pinto, PH, Silvestre, JF. Consensus on the Diagnostic Algorithm for Chronic Nodular Prurigo. Actas Dermo-Sifiliograficas. 2024; 115(10)DOI:10.1016/j.ad.2024.03.035. PMID:38663729. IF:(Q/D).

01/11/2024 Allergic contact dermatitis in adults with and without atopic dermatitis: Evaluation of the Spanish Contact Dermatitis Registry (REIDAC)

Chicharro, P, Munera-Campos, M, Zaragoza-Ninet, V, Giménez-Arnau, A, González-Pérez, R, Miquel-Miquel, FJ, Córdoba-Guijarro, S, Sanz-Sánchez, T, Ruiz-González, I, Silvestre-Salvador, JF, Serra-Baldrich, E, Borrego, L, Pastor-Nieto, MA, de Frutos, FJO, Mercader-García, P, Heras-Mendaza, F, Fernández-Redondo, V, Rodríguez-Serna, M, Hervella-García, M, Carrascosa, JM, Gallego-Descalzo, MA, García-Doval, I, Sánchez-Pérez, J. Allergic contact dermatitis in adults with and without atopic dermatitis: Evaluation of the Spanish Contact Dermatitis Registry (REIDAC). CONTACT DERMATITIS. 2024; 91(5)DOI:10.1111/cod.14672. PMID:39138883. IF:4.600(Q1/1D).

30/10/2024 Dupilumab treatment in paediatric atopic dermatitis (2-18 years): Spanish multicentre retrospective real-world study

Iznardo, H, Roé, E, Vicente, A, Prat, C, Casals, M, Martín-Santiago, A, Esteve, A, Viñas, M, Munera-Campos, M, Corella, F, Mollet, J, Figueras-Nart, I, Vila, A, Soria, X, Azón-Masoliver, A, Marqués-Martín, L, Nadal-Lladó, C, Bel, S, Pujol-Montcusí, J, Bertolín-Colilla, M, Curto-Barredo, L, Melé-Ninot, G, Evole, M, Berbegal, L, Puig, L, Baselga, E. Dupilumab treatment in paediatric atopic dermatitis (2-18 years): Spanish multicentre retrospective real-world study. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2024; 50(1)DOI:10.1093/ced/llae300. PMID:39093288. IF:2.800(Q2/4D).

02/10/2024 Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies

Schwartzman, S, Puig, L, Cohen, AD, Khattri, S, Jossart, C, Diaz, C, Garrelts, A, Ngantcha, M, Eberhart, N, Eleftheriadi, A, Tangsirisap, N, Schuster, C, Gottlieb, AB. Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies. Expert Opinion On Drug Safety. 2024; 23(10)DOI:10.1080/14740338.2024.2399092. PMID:39234767. IF:3.100(Q2/4D).

01/10/2024 Breakout Session and Report Back: Collaboration of Rheumatologists and Dermatologists for the Care of Patients With Psoriatic Disease

Stolnicki, DK, Coates, LC, Gollins, CE, Koppikar, S, Perez-Chada, LM, Puig, L, Ogdie, A, Deodhar, A, Ritchlin, C, Hwang, ST, Goldenstein-Schainberg, C. Breakout Session and Report Back: Collaboration of Rheumatologists and Dermatologists for the Care of Patients With Psoriatic Disease. JOURNAL OF RHEUMATOLOGY. 2024; 51DOI:10.3899/jrheum.2024-0621. PMID:39089830. IF:3.400(Q2/3D).

01/09/2024 Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial

Puig, L, Costanzo, A, de Jong, EMGJ, Torres, T, Warren, RB, Wapenaar, R, Wegner, S, Gorecki, P, Gramiccia, T, Jazra, M, Buyze, J, Conrad, C. Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial. Dermatology and Therapy. 2024; 14(9)DOI:10.1007/s13555-024-01245-6. PMID:39153060. IF:4.200(Q1/1D).

01/09/2024 A Non-Interventional, Multicenter Study to Characterize the Socio-Demographics, Clinical Characteristics, and Management of Generalized Pustular Psoriasis Patients in Spain: IMPULSE Study

Puig, L, Belloso, RI, Rivera-Díaz, R, Sánchez, JM, Fernández-Freire, LR, Sahuquillo-Torralba, A, Ruiz-Villaverde, R. A Non-Interventional, Multicenter Study to Characterize the Socio-Demographics, Clinical Characteristics, and Management of Generalized Pustular Psoriasis Patients in Spain: IMPULSE Study. DERMATOLOGY. 2024; 240(5-6)DOI:10.1159/000540019. PMID:39019021. IF:2.700(Q2/4D).

01/09/2024 Safety in Patients with Latent Tuberculosis Who Received Concomitant Anti-Tuberculosis Medications: Analysis of 11 Studies of Guselkumab in Psoriatic Disease

Puig, L, Tsai, TF, Soriano, ER, Bhutani, T, Miller, M, Kollmeier, AP, Li, S, You, Y, Petrick, M, Li, HW, Patel, H, Lavie, F, Gooderham, M, Londo o, A, Lebwohl, M, Nash, P. Safety in Patients with Latent Tuberculosis Who Received Concomitant Anti-Tuberculosis Medications: Analysis of 11 Studies of Guselkumab in Psoriatic Disease. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).

01/09/2024 Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension

Tha i, D, Puig, L, Merola, JF, Jullien, D, Costanzo, A, Wang, M, Deherder, D, Pinto, JML, Lebwohl, M. Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).